Innovative Molecules Doses First Patient in Phase 2a Trial of Helicase-Primase Inhibitor Adibelivir for Recurrent Genital Herpes
核心洞察
Innovative Molecules GmbH has dosed the first patient in its Phase 2a proof-of-concept trial evaluating adibelivir (搜索) (IM-250) for recurrent genital herpes (搜索).
Adibelivir (搜索) is a novel oral helicase-primase (搜索) inhibitor with a mechanism distinct from nucleoside analogues, potentially addressing acyclovir-resistant HSV strains.
The study will assess safety, antiviral activity, pharmacokinetics, and clinical efficacy, with HSV shedding reduction as a key endpoint predictive of downstream suppression benefit.
MUNICH, June 25, 2026 — Innovative Molecules GmbH announced that the first patient has been dosed in its Phase 2a clinical trial of adibelivir (搜索) (IM-250), a novel oral helicase-primase (搜索) inhibitor, for the treatment of recurrent genital herpes (搜索). The milestone advances the Munich-based biotechnology company into late-stage clinical development and marks the beginning of proof-of-concept evaluation for its lead antiviral program.
The Phase 2a study is designed to evaluate the safety, antiviral activity, pharmacokinetics, and clinical efficacy of adibelivir (搜索) in patients with recurrent genital herpes (搜索). The trial design reflects the company's strategy to demonstrate both target engagement and meaningful patient benefit within a single efficient cohort before committing to a larger registrational program.
"This milestone reflects the continued maturation of Innovative Molecules into a late-stage clinical biotechnology company," said Florian Vogel, Chief Executive Officer of Innovative Molecules. "The first patient dosed in our Phase 2a trial represents a major step toward unlocking the full value of adibelivir (搜索) and brings us closer to delivering a transformative therapy for patients affected by herpes simplex–associated diseases."
A Differentiated Mechanism of Action
Adibelivir (搜索) is a selective helicase-primase (搜索) inhibitor that disrupts herpes simplex virus (HSV) replication by blocking the viral helicase-primase complex, a mechanism entirely distinct from currently available nucleoside analogues. This mechanistic distinction carries clinical significance: patients who harbor acyclovir-resistant HSV strains carry mutations in viral thymidine kinase, which nucleoside analogues require for activation. Those mutations leave helicase-primase function completely intact, positioning adibelivir as a potential therapeutic option for this underserved population.
Recurrent genital herpes (搜索) affects an estimated 81 to 98 cases per 100,000 person-years in the United States alone. Despite this substantial disease burden, nucleoside analogues have anchored standard care since acyclovir's FDA approval in 1985, leaving a four-decade gap in therapeutic innovation that Innovative Molecules aims to address.
Key Endpoints and What to Watch
The single result to watch from the Phase 2a readout is antiviral activity measured as reduction in HSV shedding. Shedding frequency is the endpoint with the strongest track record for predicting downstream efficacy in suppression trials. A clear signal on this measure would provide Innovative Molecules with both the mechanistic validation and clinical leverage needed to advance toward a pivotal trial design with confidence.
Expanding the Herpesvirus Franchise
In parallel with the adibelivir (搜索) program, Innovative Molecules is advancing a novel antiviral program targeting Epstein-Barr virus (搜索) (EBV), one of the most prevalent and clinically significant human viral infections worldwide. The EBV program is currently progressing through IND-enabling activities, with a development candidate expected to enter clinical development following completion of ongoing preclinical work.
The strategic rationale for this pipeline expansion rests on a conserved biological target: the helicase-primase (搜索) complex is preserved across herpesviruses, meaning preclinical learnings from the HSV program can meaningfully inform EBV program design without requiring a new mechanism of action.
"With a Phase 2a asset in HSV and an EBV program approaching clinical readiness, Innovative Molecules is uniquely positioned as a leading developer of next-generation therapies targeting herpesviruses," said Joachim Rothe, Chairman of Innovative Molecules' advisory board and Partner at EQT Life Sciences (搜索).
The company raised a €20 million Series A in 2021 led by LSP (搜索), with EQT Life Sciences (搜索) also represented on the advisory board, providing an investor base with appetite for a multi-asset herpesvirus development strategy.